BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9501406)

  • 21. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts.
    Kamble R; Pant S; Selby GB; Kharfan-Dabaja MA; Sethi S; Kratochvil K; Kohrt N; Ozer H
    Transfusion; 2005 Jun; 45(6):874-8. PubMed ID: 15934984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of bone-marrow cell cryopreservation using long-term cultures].
    Mellado-Damas N; Noguerol P; Carmona M; Rodríguez JM
    Sangre (Barc); 1997 Feb; 42(1):17-20. PubMed ID: 9229798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods.
    Testoni N; Lemoli RM; Martinelli G; Carboni C; Pelliconi S; Ottaviani E; Ruggeri D; Rizzi S; Motta MR; Visani G; Tura S
    Bone Marrow Transplant; 1998 Dec; 22(11):1065-70. PubMed ID: 9877268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
    Vogelsang G; Bitton R; Piantadosi S; Altomonte V; Horn T; Jones R; Miller C; Marcellus D; Abrams R; Hess A
    Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacteriological infections during the first hundred days of allogenic bone marrow transplantation--experience from Oman.
    Ghosh K; Shenoy AK; Al-Mahrooqi Z
    J Assoc Physicians India; 2002 Jul; 50():910-2. PubMed ID: 12126346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions.
    Huang XJ; Chang YJ; Zhao XY
    Transpl Immunol; 2007 Apr; 17(3):193-7. PubMed ID: 17331846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
    Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
    Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow aspiration, biopsy, and culture in the evaluation of HIV-infected patients for invasive mycobacteria and histoplasma infections.
    Akpek G; Lee SM; Gagnon DR; Cooley TP; Wright DG
    Am J Hematol; 2001 Jun; 67(2):100-6. PubMed ID: 11343381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases.
    Alessandrino P; Bernasconi P; Caldera D; Colombo A; Bonfichi M; Malcovati L; Klersy C; Martinelli G; Maiocchi M; Pagnucco G; Varettoni M; Perotti C; Bernasconi C
    Bone Marrow Transplant; 1999 Mar; 23(6):533-7. PubMed ID: 10217182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria?
    Kelly M; Roy DC; Labbe AC; Laverdiere M
    Bone Marrow Transplant; 2006 Aug; 38(3):183-8. PubMed ID: 16785868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo expansion of bone marrow from breast cancer patients: reduction in tumor cell content through passive purging.
    Lundell BI; Vredenburgh JJ; Tyer C; DeSombre K; Smith AK
    Bone Marrow Transplant; 1998 Jul; 22(2):153-9. PubMed ID: 9707023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients.
    Hammarström V; Pauksen K; Björkstrand B; Simonsson B; Oberg G; Ljungman P
    Bone Marrow Transplant; 1998 Jul; 22(1):67-71. PubMed ID: 9678798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
    Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
    Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity of autologous bone marrow graft infusion.
    Davis J; Rowley SD; Santos GW
    Prog Clin Biol Res; 1990; 333():531-40. PubMed ID: 2308999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM.
    Lioznov M; Dellbrügger C; Sputtek A; Fehse B; Kröger N; Zander AR
    Bone Marrow Transplant; 2008 Jul; 42(2):121-8. PubMed ID: 18391988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation.
    Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G
    Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.